Graham P. Bunn has been the president of GB Consulting LLC, in Pennsylvania, since 2000 and provides regulatory compliance guidance and technical consulting services for pharmaceutical, biotechnology, and other FDA‑related industries. His experience includes supporting and leading teams for quality systems assessments, regulatory action responses and remediations (FDA483, Warning Letter, Consent Decree), and preparing sites to host regulatory inspections. He has developed and facilitated numerous highly interactive learning workshops worldwide, including Aseptic Training Programs, Batch Record Reviews, QA on the Floor, and aseptic training support for Compounding Centers. Before founding GB Consulting LLC, Graham gained extensive experience through various management positions in the pharmaceutical industry with SmithKline Beecham PLC (GlaxoSmithKline PLC), Wyeth Pharmaceuticals (Pfizer), and Astra Merck Inc. (AstraZeneca PLC). His career includes management responsibilities as a corporate compliance auditor, quality assurance, validation, and clinical trials manufacturing and packaging. Graham is the editor of Good Manufacturing Practices for Pharmaceuticals and Good Laboratory Practices for Non‑Clinical Studies and the author of several book chapters/journal articles. Graham received a BSc in pharmacy from Brighton University, England, and an MSc in Quality Assurance and Regulatory Affairs from Temple University, Philadelphia, and is a member of the Regulatory Affairs Professional Society (RAPS).

• PrefaceAbout the EditorList of ContributorsIntroduction1 Regulatory Application Requirements Shanthi Ganeshan and Connie Freund2 An overview of Good Clinical Practices John Klein and Sonya Edgerton 3 Quality by Design, Critical to Quality Factors - ICH E8 (R1)Sam Sather and Jennifer Lawyer4 Good Clinical Practice ICH E6 (R2 and R3) John Klein and Sonya Edgerton 5 Clinical Safety Data Management ICH E2A Karen Truhe 6 21 CFR 50 – Informed Consent Joe Near 7 21 CFR 54 – Financial Disclosure Glenda Guest 8 21 CFR 56 – Institutional Review BoardsAurea Flores 9 Protected Health Information and Privacy in Clinical Trials (HIPAA) Sam Sather 10 Good Pharmacovigilance Practices (GVP) Jessica Chu11 Data Integrity and 21CFR11 for GCPs Randall Basinger 12 Preparing for FDA inspections at sponsor/investigator sites Tommy Lee and Sam Sather 13 Regulations relating to the Placebo response in Clinical research Graham Bunn and Arthur Ooghe

Graham P. Bunn has been the president of GB Consulting LLC, in Pennsylvania, since 2000 and provides regulatory compliance guidance and technical consulting services for pharmaceutical, biotechnology, and other FDA‑related industries. His experience includes supporting and leading teams for quality systems assessments, regulatory action responses and remediations (FDA483, Warning Letter, Consent Decree), and preparing sites to host regulatory inspections. He has developed and facilitated numerous highly interactive learning workshops worldwide, including Aseptic Training Programs, Batch Record Reviews, QA on the Floor, and aseptic training support for Compounding Centers. Before founding GB Consulting LLC, Graham gained extensive experience through various management positions in the pharmaceutical industry with SmithKline Beecham PLC (GlaxoSmithKline PLC), Wyeth Pharmaceuticals (Pfizer), and Astra Merck Inc. (AstraZeneca PLC). His career includes management responsibilities as a corporate compliance auditor, quality assurance, validation, and clinical trials manufacturing and packaging. Graham is the editor of Good Manufacturing Practices for Pharmaceuticals and Good Laboratory Practices for Non‑Clinical Studies and the author of several book chapters/journal articles. Graham received a BSc in pharmacy from Brighton University, England, and an MSc in Quality Assurance and Regulatory Affairs from Temple University, Philadelphia, and is a member of the Regulatory Affairs Professional Society (RAPS).

• PrefaceAbout the EditorList of ContributorsIntroduction1 Regulatory Application Requirements Shanthi Ganeshan and Connie Freund2 An overview of Good Clinical Practices John Klein and Sonya Edgerton 3 Quality by Design, Critical to Quality Factors - ICH E8 (R1)Sam Sather and Jennifer Lawyer4 Good Clinical Practice ICH E6 (R2 and R3) John Klein and Sonya Edgerton 5 Clinical Safety Data Management ICH E2A Karen Truhe 6 21 CFR 50 – Informed Consent Joe Near 7 21 CFR 54 – Financial Disclosure Glenda Guest 8 21 CFR 56 – Institutional Review BoardsAurea Flores 9 Protected Health Information and Privacy in Clinical Trials (HIPAA) Sam Sather 10 Good Pharmacovigilance Practices (GVP) Jessica Chu11 Data Integrity and 21CFR11 for GCPs Randall Basinger 12 Preparing for FDA inspections at sponsor/investigator sites Tommy Lee and Sam Sather 13 Regulations relating to the Placebo response in Clinical research Graham Bunn and Arthur Ooghe

Graham P. Bunn has been the president of GB Consulting LLC, in Pennsylvania, since 2000 and provides regulatory compliance guidance and technical consulting services for pharmaceutical, biotechnology, and other FDA‑related industries. His experience includes supporting and leading teams for quality systems assessments, regulatory action responses and remediations (FDA483, Warning Letter, Consent Decree), and preparing sites to host regulatory inspections. He has developed and facilitated numerous highly interactive learning workshops worldwide, including Aseptic Training Programs, Batch Record Reviews, QA on the Floor, and aseptic training support for Compounding Centers. Before founding GB Consulting LLC, Graham gained extensive experience through various management positions in the pharmaceutical industry with SmithKline Beecham PLC (GlaxoSmithKline PLC), Wyeth Pharmaceuticals (Pfizer), and Astra Merck Inc. (AstraZeneca PLC). His career includes management responsibilities as a corporate compliance auditor, quality assurance, validation, and clinical trials manufacturing and packaging. Graham is the editor of Good Manufacturing Practices for Pharmaceuticals and Good Laboratory Practices for Non‑Clinical Studies and the author of several book chapters/journal articles. Graham received a BSc in pharmacy from Brighton University, England, and an MSc in Quality Assurance and Regulatory Affairs from Temple University, Philadelphia, and is a member of the Regulatory Affairs Professional Society (RAPS).

• PrefaceAbout the EditorList of ContributorsIntroduction1 Regulatory Application Requirements Shanthi Ganeshan and Connie Freund2 An overview of Good Clinical Practices John Klein and Sonya Edgerton 3 Quality by Design, Critical to Quality Factors - ICH E8 (R1)Sam Sather and Jennifer Lawyer4 Good Clinical Practice ICH E6 (R2 and R3) John Klein and Sonya Edgerton 5 Clinical Safety Data Management ICH E2A Karen Truhe 6 21 CFR 50 – Informed Consent Joe Near 7 21 CFR 54 – Financial Disclosure Glenda Guest 8 21 CFR 56 – Institutional Review BoardsAurea Flores 9 Protected Health Information and Privacy in Clinical Trials (HIPAA) Sam Sather 10 Good Pharmacovigilance Practices (GVP) Jessica Chu11 Data Integrity and 21CFR11 for GCPs Randall Basinger 12 Preparing for FDA inspections at sponsor/investigator sites Tommy Lee and Sam Sather 13 Regulations relating to the Placebo response in Clinical research Graham Bunn and Arthur Ooghe